Cartesian Therapeutics, Inc.
RNAC
$10.79
-$0.46-4.09%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -72.91% | 244.93% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -72.91% | 244.93% | |||
| Cost of Revenue | 41.96% | -88.72% | |||
| Gross Profit | -764.00% | 98.55% | |||
| SG&A Expenses | -12.93% | 17.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.83% | 24.99% | |||
| Operating Income | 0.36% | -14.29% | |||
| Income Before Tax | 189.70% | -77.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 189.70% | -72.73% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 189.70% | -72.73% | |||
| EBIT | 0.36% | -14.29% | |||
| EBITDA | -2.36% | -11.07% | |||
| EPS Basic | 187.65% | -44.36% | |||
| Normalized Basic EPS | -7.18% | -1.92% | |||
| EPS Diluted | 185.88% | -40.12% | |||
| Normalized Diluted EPS | -5.30% | -1.92% | |||
| Average Basic Shares Outstanding | 0.30% | 1.89% | |||
| Average Diluted Shares Outstanding | 2.10% | 1.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||